Dialysis Clinic Inc.

“H. Keith johnson, md, doug johnson, md, and ken johnson have a family relationship.”

“Form 990 is reviewed by the president and cfo prior to releasing it's information to an independent accounting firm for review. The form 990 is then presented to the board where an opportunity is given to review and make changes prior to filing.”

“The conflict of interest policy is contained in the company's written standards of conduct that require acknowledgement of compliance by key employees. The company maintains an active compliance department to monitor and enforce policies.”

“The company utilizes comparability data for determining compensation. No independent review of this data was conducted during the year.”

“The company has not publicized governing documents, conflict of interest policies, and financial statements.”

“The primary responsibility of dci is to perceive, initiate, and provide comprehensive patient care. We serve society by providing care for patients with end-stage renal disease. Our goal is complete patient rehabilitation. We recognize the patient as an individual resulting from his or her genetics, life experience, habits, beliefs, and emotions; and as a member of his or her family and the community. The application of comprehensive care is on a personal level. We become acquainted with our patient as a person and seek to understand his or her problems and needs - physical, emotional, spiritual, and social. In 2016, dci employed 6373 people and provided dialysis treatments to 21,642 patients in 244 clinics located in 28 states throughout the united states. Dci, serving as the largest non-profit dialysis provider in the us, is noted for providing quality care. The united states renal data system (usrds) 2016 atlas showed dci to have the lowest smr [standardized mortality ratio] in 2014 at 0.92. The usrds went on to show that dci had the lowest shr [standardized hospitalization ratio], at 0.92. Dci offers all modalities of end stage renal disease (esrd) treatment, which include in-center hemodialysis, in-center nocturnal hemodialysis, in-center self-care hemodialysis, home hemodialysis, continuous ambulatory peritoneal dialysis, and continuous cycling peritoneal dialysis. In 2016 dci provided a total of 2,468,748 treatments. Dci was established as a nonprofit corporation, in hope of generating funds for research in order that the methods for treatment of esrd patients might be improved. We are not content to dialyze the next group of patients in the same imperfect way that the last group was dialyzed without at least making the attempt to better the patient's lot through research. As a corollary to this, education of esrd health care professionals is another goal to which dci resources are dedicated to support. Dci's research commitment includes providing a collaborative relationship in the conduct of clinical trials between dci clinics, physician/investigators, and the pharmaceutical industry. In an effort to facilitate the best care and make available to our patients state of the art clinical studies, dci has established the office of clinical research. Our experience in clinical research is a valuable resource for nephrology physician/investigators. Dci has expert knowledge in federal regulations, hipaa, medicare clinical trial policy, good clinical practice, and federal wide assurances. The dci office of clinical research provides all of the resources necessary to conduct clinical trials in an efficient, safe manner, while instilling industry best practices and producing quality data. As a non-profit 501(c)(3) organization, dci dedicates a significant portion of all monies generated to be utilized for kidney related research, education and other uses consistent with the company charter. Such programs might involve research studies, training, education, clinical, and patient care activities. In 2016, dci contributed over $3.3 million dollars to research, more than $4.1 million to education, and approximately $2.9 million dollars to development. Such contributions have a diverse and potentially powerful impact on society. - dci provided $365,722 to support the study, "an exploratory analysis of aki patient population and healthcare service utilization at end of life: does palliative care improve end-of-life outcomes?" the study will explore quality of life from the point-of-view of diverse patients with ckd in order to examine whether there are difference in patient-expressed values regarding the standardized health-related quality of life (hrqol) assessment related to patient race, ethnicity, or gender. - $346,599 was allocated to study "mechano-growth factor (mgf) roles in diabetic glomerulosclerosis - a new factor promoting diabetic kidney disease." this research will characterize the role of a new growth factor identified”

“Unrealized income/loss from joint ventures -467,339. Acquisition of minority interest in joint ventures -438,386.”